The response to anti-checkpoint blockade therapy can be influenced by tumor-infiltrating immune cells, and upregulation of some immunological checkpoint genes, such as PD-1 and CTLA-4, can be due to tumor-infiltrating CD4+ T cells 38. This evidence concerns the gene PDCD1 and neoplasm.